Clinical Trial Update: Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034) [Phase 3]

View source ↗

Summary

Phase 3 pediatric trial of boceprevir with peginterferon alfa-2b plus ribavirin for chronic hepatitis C genotype 1 was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Boceprevir (boceprevir)
• Peginterferon alfa-2b (Peginterferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Hepatitis C | Phase 3 | Status: WITHDRAWN